Latest Financial Health News

Butn Limited reported a modest net cash increase from operating activities in the December 2024 quarter, ending with a strong cash balance of $16.8 million. The fintech company’s latest cash flow report reveals ongoing investment and notable payments to related parties.

Platina Resources reports promising gold mineralisation at its Challa Gold Project and secures a government grant to fund deep drilling at Xanadu, maintaining a strong cash position of $12.3 million.

Mayfield Group Holdings has declared a $5 million special dividend alongside its interim payout, signaling robust financial health and confidence in sustained growth.

London City Equities Limited reports a robust 12% increase in its investment portfolio for the half year ending December 2024, driven by strong Fiducian Group performance and strategic share sales, enabling higher dividend payouts despite ongoing legal challenges.

Argosy Minerals has reported significant progress on its flagship Rincon Lithium Project, including an upgraded mineral resource estimate and advancing engineering and feasibility studies toward a 12,000tpa lithium carbonate operation.

Supply Network Limited projects a solid half-year profit of $19.8 million and announces a fully franked interim dividend of 32.0 cents per share, signaling steady financial health ahead of its full results.

Global Masters Fund Limited's latest quarterly report confirms compliance with all financial obligations and highlights a recent interest rate increase on its convertible notes, supported by a robust loan-to-value ratio.

ECP Emerging Growth Limited has reported steady financial health and full compliance with its convertible notes obligations for the quarter ended December 2024, maintaining a conservative loan-to-value ratio and an unchanged conversion price.

Volt Resources Limited has successfully repaid a AU$500,000 loan to RiverFort Global Opportunities, underscoring its financial discipline amid ongoing graphite project developments.

Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.

SomnoMed Limited reported a solid cash flow performance for Q4 2024, with operating activities generating a net inflow of $1.525 million and ending the quarter with $18.5 million in cash reserves.

SomnoMed reports a robust 19.8% revenue increase in Q2 FY25 and updates its full-year guidance, reflecting strong demand and operational improvements amid ongoing production enhancements.